Corporate Update: Eurofins Scientific SE Reports Strong First‑Half Performance and Strategic Acquisitions
Eurofins Scientific SE announced that its first‑half earnings surpassed expectations, driven by both organic revenue growth and the successful integration of newly acquired businesses. Adjusted earnings per share improved materially, and the company’s revenue trajectory was supported by a combination of internal expansion initiatives and incremental sales from acquisitions completed during the period.
Financial Highlights
| Metric | First‑Half 2025 | YoY Change |
|---|---|---|
| Revenue | €3.12 bn | +12 % |
| Adjusted EPS | €1.83 | +18 % |
| Adjusted EBITDA Margin | 23.6 % | +1.4 pp |
The company reiterated its guidance for the remainder of fiscal 2026 and for fiscal 2027, maintaining a target of mid‑single‑digit organic growth. Eurofins plans a steady pace of acquisitions, each expected to contribute roughly €250 million in annualized revenue. Management also confirmed its outlook for adjusted EBITDA margin improvement, aiming to reach a level above the previous year’s figure and approaching the target set for 2027.
Growth Strategy and Acquisition Profile
Eurofins highlighted its strategy of leveraging growth in end markets such as biopharmaceuticals and other life‑science testing services. A key transaction announced during the earnings call was the acquisition of the Life Sciences Testing Services division from Element Materials Technology in North America. The $400 million deal is expected to broaden Eurofins’ presence in the region and enhance its service portfolio, particularly in analytical testing for drug discovery, formulation development, and regulatory compliance.
This acquisition follows a pattern of targeted purchases designed to support long‑term expansion goals. The company’s portfolio now includes a broader range of services such as in‑vitro diagnostics, environmental monitoring, and food safety testing, positioning it to capture cross‑sell opportunities across its client base.
Market Context
European equity indices were pressured by geopolitical tensions and rising oil prices, leading to a decline in several European stocks, including Eurofins. The company’s shares experienced a modest drop in line with broader sector weakness, although the decline was less pronounced than in some peers. Market sentiment remained cautious amid concerns over inflation, potential interest‑rate adjustments by central banks, and heightened spending on artificial‑intelligence infrastructure that has weighed on technology valuations.
Despite these macro‑economic headwinds, Eurofins’ performance and strategic acquisitions position it to pursue its growth targets while navigating a volatile environment. The firm’s disciplined approach to organic expansion and selective acquisition activity provides a balanced risk‑reward profile for investors and stakeholders alike.
